



## **Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference**

January 2, 2025

DUBLIN, Jan. 2, 2025 /PRNewswire/ -- [Alkermes plc](#) (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 43<sup>rd</sup> Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 15, 2025 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on [www.alkermes.com](http://www.alkermes.com) and will be archived for 14 days.

### **About Alkermes plc**

Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at [www.alkermes.com](http://www.alkermes.com).

Alkermes Contact:  
Jamie Constantine  
Investor Relations  
+1 781 873 2402



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/alkermes-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302341496.html>

SOURCE Alkermes plc